|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2003-7-22
|
|
pubmed:abstractText |
Hepatitis C virus (HCV) is prevalent in patients with end stage renal disease who are on dialysis. Liver disease from HCV is a cause of substantial morbidity and mortality after kidney transplantation in infected recipients. Effective treatment of chronic HCV is needed in this group of patients. We aimed to determine from the literature the efficacy and safety of interferon monotherapy in dialysis patients with chronic HCV.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0002-9270
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
98
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1610-5
|
|
pubmed:dateRevised |
2005-11-16
|
|
pubmed:meshHeading |
pubmed-meshheading:12873587-Antiviral Agents,
pubmed-meshheading:12873587-Dose-Response Relationship, Drug,
pubmed-meshheading:12873587-Drug Administration Schedule,
pubmed-meshheading:12873587-Genotype,
pubmed-meshheading:12873587-Hepacivirus,
pubmed-meshheading:12873587-Hepatitis C, Chronic,
pubmed-meshheading:12873587-Humans,
pubmed-meshheading:12873587-Interferons,
pubmed-meshheading:12873587-Kidney Failure, Chronic,
pubmed-meshheading:12873587-Renal Dialysis,
pubmed-meshheading:12873587-Safety,
pubmed-meshheading:12873587-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.
|
|
pubmed:affiliation |
Division of Digestive Diseases and Nutrition, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
|
|
pubmed:publicationType |
Journal Article,
Review
|
